Competitive Grants Program - Infectious Diseases

Competitive Grants Program - Infectious Diseases is sponsored by Pfizer. Pfizer's Competitive Grants Program supports independent initiatives (e. g.

, research, quality improvement, or education) that improve patient outcomes in areas of unmet medical need aligned with Pfizer's medical and/or scientific strategies, including infectious diseases.

Competitive Grants Program | Pfizer Funding Global Health Through Grants Competitive Grants Program Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP.

The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.

Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Implementing Shared Decision Making in Hemophilia Patient Care Release Date: May 26, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Rare Disease USA September 17, 2026 Improving the Vaccination Environment to Prevent Respiratory Infectious Diseases in Older Adults and High-Risk Individuals Release Date: June 24, 2026 Review Process: Pfizer Internal View RFP (PDF) Quality Improvement Vaccines Japan September 30, 2026 Improving Shared Decision Making in Hemophilia: Visiting Professorship Program - 2026, Semester 2 Release Date: June 25, 2026 Partner: Hemostasis & Thrombosis Research Society (HTRS) Review Process: Expert Review Panel View RFP (PDF) Education Rare Disease USA September 17, 2026 Development of Healthcare Professionals with Advanced Expertise in Preventive Strategies in Pediatric Infectious Diseases Release Date: June 26, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Vaccines Japan September 30, 2026 Current and Emerging Therapies: The future of Recurrent or Metastatic (r/m) Cervical Cancer Release Date: July 1, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology USA September 24, 2026 The Role of RSV in Functional Decline and Healthcare Dependency in Hospitalized Adults Release Date: July 6, 2026 Review Process: Expert Review Panel View RFP (PDF) Research Vaccines Italy October 19, 2026 Improving the Quality and Standardization of Pneumococcal Diagnostic Pathways in Pediatric and Adult Populations Release Date: July 6, 2026 Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Vaccines Italy October 19, 2026 Interventional Research Studies of Brentuximab Vedotin-Based Novel Combinations in AITL and PTCL-NOS Release Date: July 15, 2026 Review Process: Pfizer Internal View RFP (PDF) Research Oncology USA September 17, 2026 Optimizing Early Biomarker Testing to Guide Clinical Decision-Making in Colorectal Cancer Across Latin America Release Date: July 24, 2026 Review Process: Pfizer Internal View RFP (PDF) Education Oncology Argentina, Brazil, Chile, Colombia, Mexico, Peru September 17, 2026 Optimizing Maternal RSV Immunization Delivery: A Systems-Based QI Initiative to Improve Uptake, Equity, and Newborn Outcomes Release Date: July 30, 2026 Partner: Society for Maternal Fetal Medicine Review Process: Expert Review Panel View RFP (PDF) Quality Improvement Vaccines USA September 17, 2026 Inflammation & Immunology Support for the Professions British Indian Ocean Territory Congo, The Democratic Republic Falkland Islands (Malvinas) French Southern Territories Heard and Mc Donald Islands Holy See (Vatican City State) Iran (Islamic Republic of) Korea, Democratic People's Rep Lao People's Democratic Republ Macedonia, The Former Yugoslav Micronesia, Federated States o Saint Vincent and the Grenadin Slovakia (Slovak Republic) South Georgia and the South Sa Svalbard and Jan Mayen Islands Tanzania, United Republic of United States Minor Outlying I Wallis and Futuna Islands Pneumococcal Disease Prevention Release Date: April 11, 2012 Review Process: View RFP (PDF) Release Date: May 8, 2012 Review Process: View RFP (PDF) Release Date: June 28, 2012 Review Process: View RFP (PDF) Pharmacy Pneumococcal Disease Prevention Release Date: June 28, 2012 Review Process: View RFP (PDF) Release Date: July 2, 2012 Review Process: View RFP (PDF) Non-Small Cell Lung Cancer Release Date: July 10, 2012 Review Process: View RFP (PDF) Cardiovascular Risk in Rheumatoid Arthritis Release Date: July 25, 2012 Review Process: View RFP (PDF) Release Date: July 26, 2012 Review Process: View RFP (PDF) Adult Pneumococcal Disease Prevention Release Date: August 29, 2012 Review Process: View RFP (PDF) Prevention of Stroke in Women Release Date: September 13, 2012 Review Process: View RFP (PDF) Oncology Educational Needs Assessments Release Date: October 22, 2012 Review Process: View RFP (PDF) Release Date: November 1, 2012 Review Process: View RFP (PDF)